Johnson & Johnson

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4781601046
USD
202.48
-2.85 (-1.39%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Johnson & Johnson stock-summary
stock-summary
Johnson & Johnson
Pharmaceuticals & Biotechnology
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Company Coordinates stock-summary
Company Details
1 Johnson And Johnson Plz , NEW BRUNSWICK NJ : 08933-0001
stock-summary
Tel: 1 732 52424551 800 9505089
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 304 Schemes (25.69%)

Foreign Institutions

Held by 709 Foreign Institutions (16.9%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Alex Gorsky
Chairman of the Board, Chief Executive Officer
Ms. Anne Mulcahy
Lead Independent Director
Dr. Mary Beckerle
Independent Director
Mr. D. Scott Davis
Independent Director
Mr. Ian Davis
Independent Director
Dr. Jennifer Doudna
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
23,741 Million
(Quarterly Results - Jun 2025)
Net Profit:
5,537 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 515,810 Million (Large Cap)

stock-summary
P/E

23.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.56%

stock-summary
Debt Equity

0.41

stock-summary
Return on Equity

25.10%

stock-summary
Price to Book

6.57